Streetbeat News

ADXN

Addex Therapeutics Ltd

https://www.addextherapeutics.com

Industry

Biotechnology

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Open

8.04

Mkt cap

13M

Volume

21K

High

8.30

P/E Ratio

-0.42

52-wk high

27.90

Low

7.79

Div yield

N/A

52-wk low

5.00

The article compares the performance of Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) to their sector this year, analyzing whether these medical stocks are lagging.

Portfolio Pulse from

November 11, 2024 | 4:00 pm

Addex Therapeutics reported a significant net loss in its provisional third quarter 2024 results compared to the second quarter. However, the company remains on track for a net profit for the nine-month period.

Portfolio Pulse from

November 11, 2024 | 6:15 am

In Tuesday's pre-market session, several health care stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also declined following its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also saw a decrease following its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

iRhythm Technologies shares surged over 20% in pre-market trading following FDA clearance for its Zio AT device. Other notable pre-market movers include Genprex, SRM Entertainment, and TC Biopharm, with significant gains, while companies like IN8bio and DMC Global saw declines.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 11:06 am

HC Wainwright & Co. has reiterated its Buy rating on Addex Therapeutics (NASDAQ:ADXN) and maintained a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:39 am

Addex Therapeutics shares rose following the release of their H2 financial results.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:29 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Prime Medicine, Traws Pharma, and Tharimmune saw notable gains, while Ensysce Biosciences and Corvus Pharma faced declines. Earnings reports influenced some stock movements.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:06 pm

Addex Therapeutics reported a Q2 2024 EPS of CHF0.08 and a cash balance of CHF3.8M. The company experienced a net profit of CHF12.879M for the period, a significant improvement from a loss of CHF2.675M in the previous year. Despite a decrease in cash and cash equivalents, the overall financial performance shows a positive turnaround.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:49 am

Addex Therapeutics reported a net profit of CHF 9.8 million for H1 2024, a significant turnaround from a CHF 5.1 million loss in H1 2023. This improvement is attributed to the sale of part of its business to Neurosterix Pharma, resulting in CHF 5.0 million in cash and a 20% equity interest in Neurosterix US holdings LLC valued at CHF 9.4 million.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 5:49 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.